Effect of Adjustment for Case Misclassification and Infection Date Uncertainty on Estimates of COVID-19 Effective Reproduction Number.


Journal

Epidemiology (Cambridge, Mass.)
ISSN: 1531-5487
Titre abrégé: Epidemiology
Pays: United States
ID NLM: 9009644

Informations de publication

Date de publication:
01 11 2021
Historique:
pubmed: 27 7 2021
medline: 2 10 2021
entrez: 26 7 2021
Statut: ppublish

Résumé

Surveillance data captured during the COVID-19 pandemic may not be optimal to inform a public health response, because it is biased by imperfect test accuracy, differential access to testing, and uncertainty in date of infection. We downloaded COVID-19 time-series surveillance data from the Colorado Department of Public Health & Environment by report and illness onset dates for 9 March 2020 to 30 September 2020. We used existing Bayesian methods to first adjust for misclassification in testing and surveillance, followed by deconvolution of date of infection. We propagated forward uncertainty from each step corresponding to 10,000 posterior time-series of doubly adjusted epidemic curves. The effective reproduction number (Rt), a parameter of principal interest in tracking the pandemic, gauged the impact of the adjustment on inference. Observed period prevalence was 1.3%; median of the posterior of true (adjusted) prevalence was 1.7% (95% credible interval [CrI]: 1.4%, 1.8%). Sensitivity of surveillance declined over the course of the epidemic from a median of 88.8% (95% CrI: 86.3%, 89.8%) to a median of 60.8% (95% CrI: 60.1%, 62.6%). The mean (minimum, maximum) values of Rt were higher and more variable by report date, 1.12 (0.77, 4.13), compared to those following adjustment, 1.05 (0.89, 1.73). The epidemic curve by report date tended to overestimate Rt early on and be more susceptible to fluctuations in data. Adjusting for epidemic curves based on surveillance data is necessary if estimates of missed cases and the effective reproduction number play a role in management of the COVID-19 pandemic.

Sections du résumé

BACKGROUND
Surveillance data captured during the COVID-19 pandemic may not be optimal to inform a public health response, because it is biased by imperfect test accuracy, differential access to testing, and uncertainty in date of infection.
METHODS
We downloaded COVID-19 time-series surveillance data from the Colorado Department of Public Health & Environment by report and illness onset dates for 9 March 2020 to 30 September 2020. We used existing Bayesian methods to first adjust for misclassification in testing and surveillance, followed by deconvolution of date of infection. We propagated forward uncertainty from each step corresponding to 10,000 posterior time-series of doubly adjusted epidemic curves. The effective reproduction number (Rt), a parameter of principal interest in tracking the pandemic, gauged the impact of the adjustment on inference.
RESULTS
Observed period prevalence was 1.3%; median of the posterior of true (adjusted) prevalence was 1.7% (95% credible interval [CrI]: 1.4%, 1.8%). Sensitivity of surveillance declined over the course of the epidemic from a median of 88.8% (95% CrI: 86.3%, 89.8%) to a median of 60.8% (95% CrI: 60.1%, 62.6%). The mean (minimum, maximum) values of Rt were higher and more variable by report date, 1.12 (0.77, 4.13), compared to those following adjustment, 1.05 (0.89, 1.73). The epidemic curve by report date tended to overestimate Rt early on and be more susceptible to fluctuations in data.
CONCLUSION
Adjusting for epidemic curves based on surveillance data is necessary if estimates of missed cases and the effective reproduction number play a role in management of the COVID-19 pandemic.

Identifiants

pubmed: 34310444
doi: 10.1097/EDE.0000000000001402
pii: 00001648-202111000-00005
pmc: PMC8478862
mid: NIHMS1724013
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

800-806

Subventions

Organisme : NIAID NIH HHS
ID : K01 AI143356
Pays : United States

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Références

Euro Surveill. 2020 Apr;25(17):
pubmed: 32372755
Emerg Infect Dis. 2006 Jan;12(1):110-3
pubmed: 16494726
PLoS Comput Biol. 2020 Dec 10;16(12):e1008409
pubmed: 33301457
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
BMC Med Inform Decis Mak. 2012 Dec 18;12:147
pubmed: 23249562
PLoS Med. 2011 Oct;8(10):e1001103
pubmed: 21990967
Spat Spatiotemporal Epidemiol. 2021 Feb;36:100401
pubmed: 33509436
Can J Public Health. 2020 Jun;111(3):397-400
pubmed: 32578184
Am J Public Health. 2020 Aug;110(8):1169-1170
pubmed: 32552029
BMC Med Res Methodol. 2020 Jun 6;20(1):146
pubmed: 32505172
Am J Epidemiol. 2004 Sep 15;160(6):509-16
pubmed: 15353409
Epidemiology. 2019 Sep;30(5):737-745
pubmed: 31205290
Epidemics. 2019 Mar;26:128-133
pubmed: 30880169
Science. 1991 Jul 5;253(5015):37-42
pubmed: 2063206
Science. 2020 Jul 10;369(6500):
pubmed: 32414780
Epidemics. 2019 Dec;29:100356
pubmed: 31624039

Auteurs

Neal D Goldstein (ND)

From the Department of Epidemiology and Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, PA.

Harrison Quick (H)

From the Department of Epidemiology and Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, PA.

Igor Burstyn (I)

From the Department of Epidemiology and Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, PA.
Department of Environmental and Occupational Health, Drexel University Dornsife School of Public Health, Philadelphia, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH